---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-22-000143"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:30:16.346615+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Denali Q3 net loss widens to $103.3M; cash at $1.11B after $296M offering

## Summary
- Net loss of $103.3M for Q3 2022 vs. $84.6M in Q3 2021; collaboration revenue fell to $3.6M from $5.3M.
- R&D expenses rose to $87.8M (up $16.2M) driven by LRRK2 milestone payment and pipeline progress.
- Cash, cash equivalents, and marketable securities totaled $1.11B as of Sep 30, 2022, plus net proceeds of $296.2M from Oct 2022 public offering.
- Phase 3 LIGHTHOUSE study of BIIB122 initiated in LRRK2-positive Parkinson's; Phase 2 COMPASS study of DNL310 enrolling in Hunter syndrome.
- Interim Phase 1 data for TAK-594/DNL593 showed substantial CSF progranulin increases supporting FTD-GRN Part B dosing.

## SEC filing metadata
- accession: 0001714899-22-000143
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/0001714899-22-000143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/dnli-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-22-000143
- JSON: https://secwatch.observer/filing/0001714899-22-000143.json
- Plain text: https://secwatch.observer/filing/0001714899-22-000143.txt

## Key facts
- Earnings Releases
  Denali Therapeutics Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $103.3 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: net loss of $103.3 million
  - Result: reported results
  source text: Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/0001714899-22-000143-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.